QUALIGEN THER.NEW DL-001
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1a clinical trial for the treatment of pancreatic cancer and other sol… Read more
Market Cap & Net Worth: QUALIGEN THER.NEW DL-001 (7R9)
QUALIGEN THER.NEW DL-001 (F:7R9) has a market capitalization of $1.99 Million (€1.93 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #42206 globally and #6533 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying QUALIGEN THER.NEW DL-001's stock price €2.63 by its total outstanding shares 737000 (737.00K).
QUALIGEN THER.NEW DL-001 Market Cap History: 2017 to 2024
QUALIGEN THER.NEW DL-001's market capitalization history from 2017 to 2024. Data shows change from $2.35 Billion to $1.99 Million (-64.88% CAGR).
QUALIGEN THER.NEW DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how QUALIGEN THER.NEW DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 7R9 by Market Capitalization
Companies near QUALIGEN THER.NEW DL-001 in the global market cap rankings as of March 19, 2026.
Key companies related to QUALIGEN THER.NEW DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
QUALIGEN THER.NEW DL-001 Historical Marketcap From 2017 to 2024
Between 2017 and today, QUALIGEN THER.NEW DL-001's market cap moved from $2.35 Billion to $ 1.99 Million, with a yearly change of -64.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | €1.99 Million | -88.57% |
| 2023 | €17.38 Million | -58.45% |
| 2022 | €41.84 Million | -88.36% |
| 2021 | €359.34 Million | -60.58% |
| 2020 | €911.59 Million | -15.44% |
| 2019 | €1.08 Billion | -77.86% |
| 2018 | €4.87 Billion | +107.66% |
| 2017 | €2.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 27th, 2025 the market cap of QUALIGEN THER.NEW DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.99 Million USD |
| MoneyControl | $1.99 Million USD |
| MarketWatch | $1.99 Million USD |
| marketcap.company | $1.99 Million USD |
| Reuters | $1.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.